Diabetes in Pregnancy Western Cape Guidelines
-
Upload
paingmyint -
Category
Documents
-
view
225 -
download
0
Transcript of Diabetes in Pregnancy Western Cape Guidelines
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
1/41
DIABETES IN PREGNANCY
Guideline for the management ofdiabetes and its complications from
pre-conception to the postnatalperiod
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
2/41
- 2
Diabetes in pregnancy
ContentsA. Introduction...................................................................................... 3
B. Background ..................................................................................... 3
C. Target group.................................................................................... 3
D. Levels of evidence........................................................................... 3
E. Methods used to collect evidence .................................................... 4
F. Guideline development ................................................................... 4
G. Introduction to the guideline............................................................. 5
1.1 Pre-conception care......................................................................... 9
1.2 Gestational diabetes....................................................................... 13
1.3 Antenatal care ................................................................................ 17
1.4 Intra-partum care............................................................................ 21
1.5 Neonatal care................................................................................. 22
1.6 Postpartum care ............................................................................. 23
Protocol A: Gestational diabetes ................................................................ 25
Protocol B: NIDDM..................................................................................... 30
Protocol C: IDDM ....................................................................................... 34
Protocol D: Management of diabetic keto-acidosis ..................................... 38
Table 1: Specific antenatal care ................................................................. 40
Table 2: Available insulin............................................................................ 41
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
3/41
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
4/41
- 4
subsequently revised by a sub-committee of the Society for Maternal and Fetal Medicine in
South Africa after input from all the members of that society. The full NICE guideline
(www.nice.org.uk/CG063fullguideline) gives details of the methods and the evidence used to
develop the guidance as well as the full literature review on which this was based. The NICE
guideline was published in March 2008, and refers to the ongoing HAPO and ACHOIS
studies, final results of which were published in May 2008 and included in this review.
E. Methods used to collect evidence
The MEDLINE database was searched for all English language publications using the key
words Diabetes, Pregnancy, Metformin, insulin, keto-acidosis, HAPO and ACHOIS
(accessed at www.ncbi.nlm.nih.gov ). Related articles were found through the linkage
function inherent in the Medline search engine as well as through the reference section of
accessed publications. All Cochrane reviews related to pregnancy and childbirth were
perused in the Cochrane library issue 3 of 2010, (full-text accessed through Wiley
InterScience at www.mrw.interscience.wiley.com). The repositories of data of the following
colleges were accessed online: Royal College of Obstetrics and Gynaecology (
www.rcog.org.uk ), American College of Obstetrics and Gynecology ( www.acog.org ) the
Royal Australian and New-Zealand College of Obstetrics and Gynaecology
(www.ranzcog.edu.au) and the Society of Obstetricians and Gynaecologists of Canada
(www.sogc.org). The World Health Organisation resource guides were accessed at
www.iwhc.org/resources and further literature searches for reviews and consensus
statements were performed using Google Scholar ( www.scholar.google.com ).
F. Guideline development
This guideline constitutes a review of the most recent (up to June 2010) literature as well as
an adaptation of the NICE guideline on diabetes in pregnancy. It was developed through a
process of review by
o The Maternal Guidelines Reference Group
o External review by experts from both academic hospitals and secondary
hospitals in the Western Cape Province.
o In addition the guidelines were discussed, reviewed and submitted for
endorsement by the Society for Maternal and Fetal Medicine in South Africa.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
5/41
- 5
External expert reviewers:
The guideline was additionally sent for peer review to two general obstetrician
gynaecologists working at secondary level hospitals, medical officers working in obstetrics at
district level, midwives at all levels of care and patient representatives.
The Maternal Guidelines Reference Group: Members (for this document)
Coordinator/Chair:
Ms E Arends: Assistant Director Maternal Child & Womans Health Sub-Directorate.
Editors:
Dr S Gebhardt Principal Specialist & Head of Department Obstetrics & Gynaecology, PaarlHospital and Clinical Coordinator, Obstetrics and Gynaecology, PGWC.
Prof E Coetzee: Principal Specialist, Department of Obstetrics & Gynaecology, University of
Cape Town and Groote Schuur Hospital.
Members:
Prof G Theron: Chief Specialist, Department of Obstetrics & Gynaecology, University ofStellenbosch and Tygerberg Hospital.
Dr C Oettl: Principal Specialist & Head of Department Obstetrics & Gynaecology, EbenDnges Hospital Worcester.
Prof S Clow: Associate Professor, Division of Nursing & Midwifery, University of Cape Town.
Dr L Schoeman, Senior Specialist, Department of Obstetrics & Gynaecology, University ofCape Town and Groote Schuur Hospital.
Dr F Patel: Senior Specialist and Head of Department, Obstetrics and Gynaecology, KarlBremer Hospital.
Prof C Nikodem: Senior Lecturer, University of Western Cape.
Ms W Kamfer: Deputy Director Maternal Neonatal & Womens Health Westcoast WinelandsRegion.
Ms S Neethling: Chief Professional Nurse; Maternal & Womans Health; Boland/Overberg
Region.
Ms L Krynauw: Chief Professional Nurse, Obstetrics and Gynaecology, Tygerberg Hospital.
Ms V Adriaans: Assistant Director Maternal Neonatal & Womens Health Metropole RegionalOffice.
Ms M Petersen: Chief Professional Nurse, Education Deptartment Mowbray MaternityHospital.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
6/41
- 6
The members of the sub-committee of the Society for Maternal and Fetal Medicine in SouthAfrica were:
Prof D Hall: Principal Specialist, Department of Obstetrics & Gynaecology, University ofStellenbosch and Tygerberg Hospital
Dr H Lombaard: Principal Specialist, Department of Obstetrics & Gynaecology, Universityof Pretoria.
Dr M Conradie: Principal Medical Officer, Division of Endocrinology, Tygerberg hospitaland Stellenbosch University
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
7/41
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
8/41
- 8
The importance of avoiding unplanned pregnancy should be an essential component of
diabetes education from adolescence for women with diabetes.
Women with diabetes who are planning to become pregnant should be offered pre-
conception care and advice before discontinuing contraception.
Antenatal care
If it is safely achievable, women with diabetes should aim to keep fasting blood glucose
between 3.5 - 5.5 mmol/l and a 2-hour post-prandial level below 7mmol/l during
pregnancy. Post-prandial monitoring should be instituted when insulin is administered 2
times per day. The HbA1c should be measured every four weeks with the aim of
maintaining this value below 6.1%.
Women with insulin-treated diabetes should be advised of the risks of hypoglycaemia and
hypoglycaemia unawareness in pregnancy, particularly in the first trimester.
During pregnancy, women who are suspected of having diabetic ketoacidosis should be
admitted immediately to a tertiary hospital (or the nearest secondary hospital in rural
areas), where they can receive both medical and obstetric care.
Women with pre-gestational diabetes should be offered nuchal translucency (NT)
ultrasound scan at 12 weeks and a fetal anomaly scan at 20 weeks.
Neonatal care
Babies of women with diabetes should be kept with their mothers unless there is a clinical
complication or there are abnormal clinical signs that warrant admission for intensive or
high care.
Postnatal care
Women who were diagnosed with gestational diabetes should be offered lifestyle advice
(including weight control, diet and exercise) and offered at least a glucose profile (as
described on page 26) at the 6-week postnatal check and annually thereafter.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
9/41
- 9
Guidance
1.1 Pre-conception care
1.1.1 Outcomes and risks for the woman and baby
1.1.1.1 Healthcare professionals should seek to empower women with diabetes
to make the experience of pregnancy and childbirth a positive one by
providing information, advice and support that will help to reduce the
risks of adverse pregnancy outcomes for the mother and the baby.
1.1.1.2 Women with diabetes who are planning to become pregnant should be
informed that establishing good glycaemic control before conception
and continuing this throughout pregnancy will reduce the risk of
miscarriage, congenital malformation, stillbirth and neonatal death. It is
important to explain that these risks can be reduced but not eliminated.
1.1.1.3 Women with diabetes who are planning to become pregnant and their
families should be offered information about how diabetes affects
pregnancy and how pregnancy affects diabetes. The information should
cover:
the role of diet, body weight and exercise
the risks of hypoglycaemia and hypoglycaemia unawareness during
pregnancy
how nausea and vomiting in pregnancy can affect glycaemic control
the increased risk of having a baby who is large for gestational age, which
increases the likelihood of birth trauma, induction of labour and caesarean
section
the need for assessment of diabetic retinopathy before and during pregnancy
the need for assessment of diabetic nephropathy before pregnancy
the importance of maternal glycaemic control during labour and birth and early
feeding of the baby in order to reduce the risk of neonatal hypoglycaemia
the possibility of transient morbidity in the baby during the neonatal period,
which may require admission to the neonatal unit
the risk of the baby developing obesity and/or diabetes in
later life.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
10/41
- 10
1.1.2 The importance of planning pregnancy and the role of contraception
1.1.2.1 The importance of avoiding unplanned pregnancy should be an
essential component of diabetes education from adolescence for
women with diabetes.
1.1.2.2 Women with diabetes who are planning to become pregnant should be
advised:
that the risks associated with pregnancies complicated by diabetes increase
with the duration of diabetes
to use contraception until good glycaemic control (assessed by HbA1c) has
been established
that glycaemic targets, glucose monitoring, medications for diabetes (including
insulin regimens for insulin-treated diabetes) and medications for
complications of diabetes will need to be reviewed before and duringpregnancy
that additional time and effort is required to manage diabetes during
pregnancy and that there will be frequent contact with healthcare
professionals. Women should be given information about the local
arrangements for support, including emergency contact numbers.
1.1.3 Diet, dietary supplements, body weight and exercise
1.1.3.1 Women with diabetes who are planning to become pregnant should be
offered individualised dietary advice.
1.1.3.2 Women with diabetes who are planning to become pregnant and who
have a body mass index above 27 kg/m2should be offered advice on
how to lose weight.
1.1.3.3 Women with diabetes who are planning to become pregnant should be
advised to take folic acid (5 mg/day) from three months before the
pregnancy until at least 12 weeks of gestation to reduce the risk of
having a baby with a neural tube defect.
1.1.4 Target ranges for blood glucose in the pre-conception period
1.1.4.1 Individualised targets for self-monitoring of blood glucose should be
agreed with women who have diabetes and are planning to become
pregnant, taking into account the risk of hypoglycaemia.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
11/41
- 11
1.1.4.2 If it is safely achievable, women with diabetes who are planning to
become pregnant should aim to maintain their HbA1c below 6.1%.
Women should be reassured that any reduction in HbA1c towards this
target is likely to reduce the risk of congenital malformations.
1.1.4.3 Women with diabetes whose HbA1c is above 10% should be strongly
advised to avoid pregnancy.
1.1.5 Monitoring blood glucose and ketones in the pre-conception period
1.1.5.1 Women with diabetes who are planning to become pregnant should be
offered monthly measurement of HbA1c.
1.1.5.2 Women with diabetes who are planning to become pregnant should be
offered a meter for self-monitoring of blood glucose.
1.1.5.3 Women with diabetes who are planning to become pregnant and whorequire intensification of hypoglycaemic therapy should be advised to
increase the frequency of self-monitoring of blood glucose (up to seven
times per day) to include fasting and a mixture of pre- and postprandial
levels.
1.1.5.4 Women with type 1 diabetes who are planning to become pregnant
should be offered ketone testing strips and advised to test for ketonuria
or ketonaemia if they become hyperglycaemic or unwell.
1.1.6 The safety of medications for diabetes before and during pregnancy
1.1.6.1 Women with diabetes may be advised to use metformin or
glibenclamide as an adjunct or alternative to insulin in the pre-
conception period and during pregnancy, when the likely benefits from
improved glycaemic control outweigh the potential for harm. All other
oral hypoglycaemic agents should be discontinued before pregnancy
and insulin substituted.
1.1.6.2 Healthcare professionals should be aware that the rapid-acting insulinanalogues (e.g. insulin human lispro; only available on a named patient
basis in the central hospitals) are safe to use during pregnancy.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
12/41
- 12
1.1.6.3 Women with insulin-treated diabetes who are planning to become
pregnant should be informed that there is insufficient evidence about the
use of long-acting insulin analogues during pregnancy. Therefore
isophane insulin (Protaphane HM/ Humulin N) remains the first choice
for intermediate/long-acting insulin during pregnancy.
1.1.7 The safety of medications for diabetic complications before and during
pregnancy
1.1.7.1 Angiotensin-converting enzyme inhibitors and angiotensin-II receptor
antagonists should be discontinued before conception or as soon as
pregnancy is confirmed. Alternative antihypertensive agents suitable for
use during pregnancy should be substituted.
1.1.7.2 Statins should be discontinued before pregnancy or as soon as
pregnancy is confirmed.
1.1.8 Removing barriers to the uptake of pre-conception care and when to offer
information
1.1.8.1 Women with diabetes should be informed about the benefits of
pre-conception glycaemic control at every contact with healthcare
professionals, including their diabetes care team, from adolescence.
1.1.8.2 The intentions of women with diabetes regarding pregnancy and
contraceptive use should be documented at each contact with theirdiabetes care team from adolescence.
1.1.8.3 Pre-conception care for women with diabetes should be given in a
supportive environment and the womans partner or another family
member should be encouraged to attend.
1.1.9 Self-management programmes
1.1.9.1 Women with diabetes who are planning to become pregnant
should be offered pre-conception care and advice before discontinuing
contraception.
1.1.10 Retinal assessment in the pre-conception period
1.1.10.1 Women with type 1 or full-blown type II diabetes seeking pre-conception
care should be offered retinal assessment at that time (unless an annual
retinal assessment has occurred within the previous 6 months) and
annually thereafter if no diabetic retinopathy is found.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
13/41
- 13
1.1.10.2 Women with diabetes who are planning to become pregnant should be
advised to defer rapid optimisation of glycaemic control until after retinal
assessment and treatment have been completed.
1.1.11 Renal assessment in the pre-conception period
1.1.11.1 Women with diabetes should be offered a renal assessment, including a
measure of microalbuminuria, before discontinuing contraception. If
serum creatinine is abnormal (120 micromol/litre or more), referral to a
nephrologist should be considered before discontinuing contraception.
1.2 Gestational diabetes
1.2.1 Risk factors for gestational diabetes
1.2.1.1 Healthcare professionals should be aware that the following can be
independent risk factors for gestational diabetes in a South African
population:
Previous gestational diabetes
Unexplained intra-uterine death with a previous pregnancy
Previous macrosomic baby > 4.5 kg
Body Mass Index at booking >40 kg/m2
Maternal age >40 years
Family history of diabetes (first-degree relative with diabetes)
Family origin with a high prevalence of diabetes (Asiatic) Acanthosis nigricans
Polycystic ovarian syndrome
1.2.2 Screening for gestational diabetes
1.2.2.1 It is only worthwhile screening for any condition if an effective therapy is
available and if that therapy is cost-effective and prevents morbidity and
mortality. In the ACHOIS study women with IGT were randomised to
treatment or no treatment. This study clearly indicated that the rate of
serious perinatal complications was significantly lower among the
infants of the treated (or intervention) group. Patients who had diabetes
according to the criteria of the 1985 WHO technical report was not
randomised and the diagnosis was revealed to their supervising
physician. The ACHOIS results therefore pertain only to mothers with
mild carbohydrate abnormalities (IGT) but still demonstrated a clinical
improvement in perinatal results for the treated pregnancies.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
14/41
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
15/41
- 15
1.2.3.2.1. Identify high risk parameters (detailed in
1.2.2.1), especially for Type 2 DM, and do 75g OGTT on those
mothers.
1.2.3.3 Glycosuria can be used as an indication for selective screening, but the
renal threshold for glucose re-absorption is frequently lower and most
pregnant women will have glycosuria intermittently during their
pregnancy. Repeated glycosuria or fasting glycosuria may therefore be
more appropriate.
1.2.4 The argument against selective screening is that 50% of all possible GDM cases
can be missed. As these studies were mainly done in the developed world this
may not be correct in a population where Type 2 DM is more prevalent. It is
unlikely that most poorly resourced countries would be able to afford universal
screening. The following is recommended:
1.2.4.1 Screening for gestational diabetes using risk factors combined with
testing of the urine for glucose is recommended in resource challenged
settings.
Do a urine test for glucose at each antenatal visit
1+ glucose or more on diagnostic strips: do a random blood glucose test
In addition,the following patients must be screened (with a glucose profile or, preferably,
with the 75g OGTT at the 26-28 weeks visit even if the urinary diagnostic strips remain
negative for glucose):
Previous gestational diabetes (do OGTT already at booking)
Unexplained intra-uterine death with a previous pregnancy
Previous macrosomic baby > 4.5 kg
Body Mass Index at booking >40 kg/m2
Maternal age >40 years
Family history of diabetes (first-degree relative with diabetes)
Family origin with a high prevalence of diabetes (Asiatic)
Acanthosis nigricans
Polycystic ovarian syndrome
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
16/41
- 16
1.2.4.2 In order to make an informed decision about screening and testing for
gestational diabetes, women should be informed that:
in most women, gestational diabetes will respond to changes in diet and
exercise
some women (between 10% and 20%) will need oral hypoglycaemic agents or
insulin therapy or both if diet and exercise are not effective in controlling
gestational diabetes
if gestational diabetes is not detected and controlled there is a small but
increased risk of birth complications such as shoulder dystocia
a diagnosis of gestational diabetes may lead to increased monitoring and
interventions during both pregnancy and labour.
1.2.4.3 The 2-hour 75 g oral glucose tolerance test (OGTT) should be used to
test for gestational diabetes. The diagnosis is made using the criteria
defined by the World Health Organization (summarised below). Women
who have had gestational diabetes in a previous pregnancy should be
offered an OGTT at booking and a further OGTT at 26-28 weeks if the
results are normal. Women with any of the other risk factors for
gestational diabetes (see above) should be offered an OGTT at the
latest at 28 weeks.
Diagnostic values:
A fasting value
5.5 mmol/l (alternative 6 mmol/l) and a 2-hour value of < 7.8 mmol/l
(alternative 8 mmol/l) excludes gestational diabetes.
A fasting value >5.5 mmol/l (alternative 6 mmol/l) or a 2-hour value 7.8 mmol/l
(alternative 8 mmol/l), venous samples after a 75g g OGTT is regarded as positive for
gestational diabetes.
An advantage of the above criteria is the correlation with treatment goals.
1.2.4.4 Women with gestational diabetes should be instructed in self-monitoring
of blood glucose levels. Targets for blood glucose control should bedetermined in the same way as for women with pre-existing diabetes.
1.2.4.5 Women with gestational diabetes should be informed that good
glycaemic control throughout pregnancy will reduce the risk of fetal
macrosomia, trauma during birth (to themselves and the baby),
induction of labour or caesarean section, neonatal hypoglycaemia and
perinatal death.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
17/41
- 17
1.2.4.6 Women with gestational diabetes should be offered information
covering:
the role of diet, body weight and exercise
the increased risk of having a baby who is large for gestational age, which
increases the likelihood of birth trauma, induction of labour and caesarean
section
the importance of maternal glycaemic control during labour and birth and early
feeding of the baby in order to reduce the risk of neonatal hypoglycaemia
the possibility of transient morbidity in the baby during the neonatal period,
which may require admission to the neonatal unit
the risk of the baby developing obesity and/or diabetes in later life.
1.2.4.7 Women with gestational diabetes should be advised to choose, where
possible, carbohydrates from low glycaemic index sources, leanproteins including oily fish and a balance of polyunsaturated fats and
monounsaturated fats.
1.2.4.8 Women with gestational diabetes whose pre-pregnancy body mass
index was above 27 kg/m2should be referred to a dietician to counsel
on calorie intake and be advised to partake in moderate exercise (of at
least 30 minutes daily).
1.2.4.9 Hypoglycaemic therapy should be considered for women with
gestational diabetes if diet and exercise fail to maintain blood glucose targets
during a period of 12 weeks.
1.2.4.10 Hypoglycaemic therapy should be considered for women with
gestational diabetes if ultrasound investigation suggests incipient fetal
macrosomia (abdominal circumference above the 75th percentile) at diagnosis.
1.3 Antenatal care
1.3.1 Target ranges for blood glucose during pregnancy1.3.1.1 Individualised targets for self-monitoring of blood glucose should be
agreed with women with diabetes in pregnancy, taking into account the
risk of hypoglycaemia.
1.3.1.2 If it is safely achievable, women with diabetes should aim to keep
fasting blood glucose between 3.5 and 5.5 mmol/litre and 2-hour
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
18/41
- 18
postprandial blood glucose below 7.0 mmol/litre during pregnancy.
Alternative values are 6 and 8 mmol/litre.
1.3.1.3 HbA1cshould ideally be performed every 4 weeks to monitor glycaemic
control with the aim of maintaining this value below 6.1%.
1.3.2 Monitoring blood glucose and ketones during pregnancy
1.3.2.1 Ideally women using insulin should be advised to test fasting blood
glucose levels and blood glucose levels 2 hours after every meal during
pregnancy. For women using oral agents, a fasting level and
measurement of HbA1c is sufficient.
1.3.2.2 Women with insulin-treated diabetes should be advised to test blood
glucose levels before going to bed at night during pregnancy.
1.3.2.3 Women with type 1 diabetes who are pregnant should be offered ketonetesting strips and advised to test for ketonuria or ketonaemia if they
become hyperglycaemic or feel unwell.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
19/41
- 19
1.3.3 Management of diabetes during pregnancy
1.3.3.1 Women with insulin-treated diabetes should be advised of the risks of
hypoglycaemia and hypoglycaemia unawareness in pregnancy,
particularly in the first trimester.
1.3.3.2 During pregnancy, women with insulin-treated diabetes should have
quick access to a concentrated glucose solution (Super-C tablets or
honey) and women with type 1 diabetes should also be given a
glucagon device for home administration. Women and their partners or
other family members should be instructed in the use of the latter.
1.3.3.3 During pregnancy, women with type 1 diabetes who become unwell
should have diabetic ketoacidosis excluded as a matter of urgency.
1.3.3.4 During pregnancy, women who are suspected of having diabetic
ketoacidosis should be admitted immediately in a secondary (if in rural
regions) or tertiary hospital for critical care, where they can receive both
medical and obstetric care.
1.3.4 Retinal assessment during pregnancy
1.3.4.1 Pregnant women with pre-existing diabetes should be offered retinal
assessment.
1.3.4.2 If retinal assessment has not been performed in the preceding
12 months, it should be offered as soon as possible after the first
contact in pregnancy in women with pre-existing diabetes.
1.3.4.3 Diabetic retinopathy should not be considered a contraindication to
rapid optimisation of glycaemic control in women who present with a
high HbA1c in early pregnancy. However women with severe
retinopathy should be closely monitored.
1.3.4.4 Women who have preproliferative diabetic retinopathy diagnosed during
pregnancy should have ophthalmological follow-up for at least 6 monthsfollowing the birth of the baby.
1.3.4.5 Diabetic retinopathy should not be considered a contraindication to
vaginal birth.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
20/41
- 20
1.3.5 Renal assessment during pregnancy
1.3.5.1 If renal assessment has not been undertaken in the preceding
12 months in women with pre-existing diabetes, it should be arranged at
the first contact in pregnancy. Do a serum creatinine and urine
diagnostic test for protein. If there is 1+ or more proteinuria, do a full 24-
hour urinary protein quantification test. If the serum creatinine isabnormal (120 micromol/litre or more) or if total protein excretion
exceeds 2 g/day, referral to a nephrologist should be considered.
Thromboprophylaxis should be considered for women with proteinuria
above 5 g/day (macroalbuminuria).
1.3.6 Screening for congenital malformations
1.3.6.1 Women with diabetes should be offered NT scanning at 12 weeks and a
fetal anomaly scan at 20 weeks.
1.3.7 Monitoring fetal growth and well-being
1.3.7.1 Pregnant women with diabetes should be offered Doppler tests of the
umbilical artery at 24 weeks (if microvascular disease or pre-existing
diabetes is present) as well as ultrasound monitoring of fetal growth and
amniotic fluid volume at 34 weeks and an estimated fetal weight and
morphometry at 38 weeks
1.3.7.2 Routine monitoring of fetal well-being before 38 weeks is not
recommended in pregnant women with diabetes, unless there is a risk
of intra-uterine growth restriction.
1.3.7.3 Women with diabetes and a risk of intra-uterine growth restriction
(microvascular disease and/or nephropathy) will require an
individualised approach to monitoring fetal growth and well-being.
1.3.8 Timetable of antenatal appointments
1.3.8.1 Women with diabetes who are pregnant should be offered immediate
contact with a special diabetic clinic (if near a tertiary center) or at leastrefer to a high risk clinic at a secondary hospital.
1.3.8.2 Women with diabetes should have contact with their diabetes care team
for assessment of glycaemic control every 2 weeks throughout
pregnancy.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
21/41
- 21
1.3.8.3 Antenatal appointments for women with diabetes should provide care
specifically for women with diabetes, in addition to the care provided
routinely for healthy pregnant women. Table 1 describes where care for
women with diabetes differs from routine antenatal care. At each
appointment women should be offered ongoing opportunities for
information and education.
1.3.9 Preterm labour in women with diabetes
1.3.9.1 Diabetes should not be considered a contraindication to antenatal
steroids for fetal lung maturation or to tocolysis.
1.3.9.2 Women with insulin-treated diabetes who are receiving steroids for fetal
lung maturation should be closely monitored and provided with
additional insulin as needed.
1.3.9.3 Betamimetic drugs should not be used for tocolysis in women
with diabetes.
1.4 Intrapartum care
1.4.1 Timing and mode of birth
1.4.1.1 Pregnant women with diabetes who have a normally grown fetus should
be offered elective birth through induction of labour, or by electivecaesarean section if indicated, after 38 completed weeks.
1.4.1.2 Diabetes should not in itself be considered a contraindication to
attempting vaginal birth after a previous caesarean section.
1.4.1.3 Pregnant women with diabetes who have an ultrasound-diagnosed
macrosomic fetus should be informed of the risks and benefits of
vaginal birth, induction of labour and caesarean section.
1.4.2 Analgesia and anaesthesia
1.4.2.1 Women with diabetes and co-morbidities such as morbid obesity or
autonomic neuropathy should be offered an anaesthetic assessment in
the third trimester of pregnancy.
1.4.2.2 If general anaesthesia is used for the birth in women with diabetes,
blood glucose should be monitored regularly (every 30 minutes) from
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
22/41
- 22
induction of general anaesthesia until after the baby is born and the
woman is fully conscious.
1.4.3 Glycaemic control during labour and birth
1.4.3.1 During labour and birth, capillary blood glucose should be monitored on
an hourly basis in women with diabetes and maintained at between 4
and 7 mmol/litre.
1.4.3.2 Women with type 1 diabetes should be considered for an intravenous
dextrose and insulin infusion from the onset of established labour.
1.4.3.3 An intravenous dextrose and insulin infusion is recommended during
labour and birth for women with diabetes whose blood glucose is not
maintained at between 4 and 7 mmol/litre. Check urine hourly for
ketones.
1.5 Neonatal care
1.5.1 Initial assessment and criteria for admission to intensive or special care
1.5.1.1 Women with diabetes should be advised to give birth in hospitals where
advanced neonatal resuscitation skills are available 24 hours a day
(secondary or tertiary hospitals).
1.5.1.2 Babies of women with diabetes should be kept with their mothers unless
there is a clinical complication or there are abnormal clinical signs thatwarrant admission for intensive or special care.
1.5.1.3 Blood glucose testing should be carried out routinely in babies of
women with diabetes according to the provincial protocol for the
management of a baby of a diabetic mother. Blood tests for
polycythaemia, hyperbilirubinaemia, hypocalcaemia and
hypomagnesaemia should be carried out for babies with clinical signs.
1.5.1.4 Babies of women with diabetes should have an echocardiogram
performed if they show clinical signs associated with congenital heart
disease or cardiomyopathy, including heart murmur. The timing of the
examination will depend on the clinical circumstances.
1.5.1.5 Babies of women with diabetes should not be transferred to community
care until they are at least 24 hours old, and not before healthcare
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
23/41
- 23
professionals are satisfied that the babies are maintaining blood glucose
levels and are feeding well.
1.5.2 Prevention and assessment of neonatal hypoglycaemia
1.5.2.1 All maternity units should have a written policy for the prevention,
detection and management of hypoglycaemia in babies of women with
diabetes.
1.5.2.2 Babies of women with diabetes who present with clinical signs of
hypoglycaemia should have their blood glucose tested and be treated
with intravenous dextrose as soon as possible.
1.6 Postnatal care
1.6.1 Breastfeeding and effects on glycaemic control
1.6.1.1 Women with insulin-treated pre-existing diabetes should return to pre-
pregnancy doses after birth and monitor their blood glucose levels
carefully to establish that the dose remains appropriate.
1.6.1.2 Women with insulin-treated pre-existing diabetes should be informed
that they are at increased risk of hypoglycaemia in the postnatal period,
especially when breastfeeding, and they should be advised to have a
meal or snack available before or during feeds.
1.6.1.3 Women who have been diagnosed with gestational diabetes shoulddiscontinue hypoglycaemic treatment immediately after birth.
1.6.1.4 Women with pre-existing type 2 diabetes who are breastfeeding can
resume or continue to take metformin and/or glibenclamide immediately
following birth but other oral hypoglycaemic agents should be avoided
while breastfeeding.
1.6.1.5 Women with diabetes who are breastfeeding should continue to avoid
any drugs for the treatment of diabetes complications that were
discontinued for safety reasons in the pre-conception period.
1.6.2 Information and follow-up after birth
1.6.2.1 Women with pre-existing diabetes should be referred back to their
routine diabetes care arrangements.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
24/41
- 24
1.6.2.2 Women who were diagnosed with gestational diabetes should have
their blood glucose tested to exclude persisting hyperglycaemia before
they are transferred to community care.
1.6.2.3 Women who were diagnosed with gestational diabetes should be
reminded of the symptoms of hyperglycaemia.
1.6.2.4 Women who were diagnosed with gestational diabetes should be
offered lifestyle advice (including weight control, diet and exercise) and
offered a glucose profile (as described on page 26) at the 6-week
postnatal check-up and annually thereafter.
1.6.2.5 Women who were diagnosed with gestational diabetes (including those
with ongoing impaired glucose regulation) should be informed about the
risks of gestational diabetes in future pregnancies and they should be
offered screening (OGTT or fasting plasma glucose) for diabetes when
planning future pregnancies.
1.6.2.6 Women who were diagnosed with gestational diabetes (including those
with ongoing impaired glucose regulation) should be offered early self-
monitoring of blood glucose or an OGTT in future pregnancies. A
subsequent OGTT should be offered if the test results in early
pregnancy are normal (see recommendation 1.2.2.4).
1.6.2.7 Women with diabetes should be reminded of the importance ofcontraception and the need for pre-conception care when planning
future pregnancies.
Further reading
1. Rowan JA, Hague WM, Gao W, Battin MR, Moore PM. Metformin versus Insulin for
the treatment of gestational diabetes. N Engl J Med 2008; 358: 2003-2015.
2. HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy
Outcomes. N Engl J Med 2008; 358: 1991-2002
3. Diabetes in pregnancy: management of diabetes and its complications from
preconception to the postnatal period. RCOG press March 2008.
4. Diagnosis and treatment of diabetic ketoacidosis. Van Zyl DG, SA Fam Pract 2008;
50: 35-39
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
25/41
- 25
PROTOCOLS FOR THE SCREENING, DIAGNOSIS AND MANAGEMENT OF DIABETES
MELLITUS IN PREGNANCY
A. Gestational diabetes
Gestational Diabetes Mellitus (GDM) is glucose intolerance with onset or firstrecognition during pregnancy. It therefore includes mothers who have Impaired Glucose
Tolerance (IGT) or Diabetes diagnosed during the index pregnancy. The diabetes need not
disappear after pregnancy and many mothers probably had unrecognised IGT or even
Diabetes prior to the pregnancy.
Screening for diabetes at the antenatal clinic:
Do a urine test for glucose with each antenatal visit:
o If 1+ glucose or more on diagnostic strips: do a random blood glucose test
In addition, the following patients must be screened [with a glucose profile or,
preferably, with a 75g Oral Glucose Tolerance Test (OGTT)]; preferably before the
visit at 28 weeks at a doctors clinic even if the urinary diagnostic strips remain
negative for glucose:
o Previous gestational diabetes (do OGTT already with booking)
o Unexplained intra-uterine death in a previous pregnancy
o Previous macrosomic baby > 4.5 kg
o Body Mass Index at booking >40 kg/m2
o Maternal age >40 years
o Family history of diabetes (first-degree relative with diabetes)
o Family origin with a high prevalence of diabetes (Asiatic)
o Acanthosis nigricans
o Polycystic ovarian syndrome
These patients are at high risk for diabetes. Most of them would have been referred to a
doctors clinic in any case, as they do not qualify for BANC.
Interpretation of a random glucose test (BANC/MOU care):
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
26/41
- 26
Interpretation of a fasting blood glucose (glucose profile) (BANC/MOU care) -do not
eat or drink anything after 22h00 the previous night (except for water) Test blood glucose
before breakfast (patient must bring her breakfast to the clinic)
5.5 or 2 hour value 7.8 mmol/l
How to do a glucose profile at the clinic:
NPO from midnight (only water allowed)
Patient brings own breakfast to clinic
Test fasting blood glucose level
Eat breakfast, repeat blood glucose test 2 hours later
Control
AIM for a fasting value of 3.5 - 5.5 mmol/l and a 2-hour post-prandial level of
below 7mmol/l. HbA1c should ideally be performed every 4 weeks to monitor
glycaemic control with the aim of maintaining this value below 6.1%.
Management of gestational diabetes at the high risk clinic:
Do thorough medical examination: look for complications of diabetes and for signs of
long-standing diabetes.
Do a baseline serum urea and creatinine determination.
Start on 7600 kJ diet and refer to dietician for advice. All diabetic pregnant patients
must do moderate exercise for 30 minutes each day.
Clinical judgement should be exercised when moving from lifestyle to medical
interventions. Certain women can be given 2 weeks to assess the impact of lifestyle
interventions. Correct dietary advice and compliance can lower serum glucose levels
significantly. However early progression to oral agents or insulin may sometimes be
necessary.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
27/41
- 27
Start on oral anti-diabetic drugs: Metformin (first choice) 500mg twice a day; increase
if needed to 850mg three times a day. Alternative choice Daonil (glybenclamide)
2.5-5 mg twice daily. Follow up in two weeks with a glucose profile. The available
evidence (poor quality but all we have) does not support combining oral agents in
pregnancy.
If there is poor control at follow up, admit the patient to hospital for better control.
While continuing with the oral medication, perform a 24 hour blood sugar monitoring
profile for additional insulin requirement (determine glucose values half an hour
before each main meal and 2 hours after the meal). Then add insulin to control blood
sugar. The following is suggested:
Begin an insulin regimen with Protophane (GREEN) [Humulin N] only. Start at
a dose of 0.2u/kg. If the calculated dose comes to more than 20 units, start
with 20 units. It is generally a good idea to start 2 units lower than the
calculated dose if the dose is less than 20 units and the patient has not been
on insulin before. Protophane should be administered 30 minutes before
bedtime and the patient should have a snack just before going to sleep.
Monitor the fasting glucose values and HbA1c. When the fasting morning
value remains high, Protophane (code GREEN) can be increased in a
stepwise fashion until fasting values are normal.
As a safety precaution monitor glucose level 4 hours after administration once
protophane has been initiated or dosages modified. If fasting values are normal but
HbA1cis raised there are post-prandial excursions. Determine glucose values half an
hour before each main meal and 2 hours after the main meal (three times a day) for
24-48 hours before any changes and then add Actrapid (YELLOW) [Humulin R] as
indicated below only once fasting values have been normalised.
Identify the meal with the largest post-prandial increase and begin with Actrapid 4
units (30 minutes prior to meal). Increase by 2 units until the post-prandial value is
within the target range. If necessary apply the same principle to other meals.
As soon as the profile is satisfactory and the patient can inject herself, she can be
discharged. Mark the antenatal card as level 3 (high risk).
Follow up at a high risk/diabetic clinic according to the schedule below.
Remember to offer home monitoring to any patient on insulin.
Review control with HbA1c 2-4 weeks after discharge along with home monitoring
values before and after meals.
Follow up of gestational diabetics at a high-risk clinic / diabetes clinic (refer to Table 1
of the guideline):
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
28/41
- 28
2 weekly until 36 weeks.
Thereafter weekly until delivery.
Rural patients can be followed up at their own clinic in conjunction with a specialist
outreach program.
Perform detail ultrasound at 20 weeks including four-chamber view of the fetal heart
and outflow tracts. Perform ultrasound fetal evaluation and weight estimation at 36-38 weeks (weight
estimation clinically or with ultrasound, if available).
Perform glucose profile with each visit
Offer induction of labour at 38 weeks if certain gestation (preferable option). If
patient opts to continue with pregnancy, do weekly fetal surveillance until 41 weeks
and then induce. If gestation uncertain, perform amniocentesis and fetal lung
maturity tests.
Opt for elective caesarean section if the estimated fetal weight is >4 kgat term
and the baby has typical diabetic morphometry (AC >90thcentile, HC 50thcentile).
Management of gestational diabetes in labour
ALL DIABETIC PATIENTS MUST DELIVER IN A HOSPITAL WITH SPECIALIST
SUPERVISION AND 24-HOUR NEONATAL RESUSCITATION FACILITIES
Stop oral hypoglycaemic agents on the day of scheduled delivery or the night before
an elective induction or caesarean section.
Do hourly blood sugar values- aim for a value of between 4 and 7 mmol/l duringdelivery (if patient still eating meals).
If this can be achieved without additional insulin, monitoring blood sugar may be all
that is needed.
As soon as patient is nil per os, start a maintenance infusion of 10 units of short-
acting (Actrapid HM or Humulin R) insulin in 1 litre of 5% dextrose and administer
intravenously at 100ml/hour.
If hourly values not maintained between 4 and 7 mmol/l:
o If blood sugar levels rise >8mmol/l, place on a maintenance infusion of 12-14
units of short-acting (Actrapid HM or Humulin R) insulin in 1 litre of 5%
dextrose. Administer at 100 ml per hour. (Discard any previous infusions).
o If blood sugar level is
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
29/41
- 29
The labour ward doctor must be present during delivery (danger of shoulder
impaction).
The doctor on call for pediatrics must be present at delivery (remind them in time).
Do not continue with oral anti-diabetic drugs after delivery
Follow up 6 weeks3 months after delivery to determine the long-term risk for
diabetes. Women who were diagnosed with gestational diabetes should be offeredlifestyle advice (including weight control, diet and exercise) and offered at least a
glucose profile (as described earlier) at the 6-week postnatal check and annually
thereafter.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
30/41
- 30
PROTOCOLS FOR THE SCREENING, DIAGNOSIS AND MANAGEMENT OF DIABETES
MELLITUS IN PREGNANCY
B. Pre-gestational (known) diabetes (non-insulin dependant)
Pregestational (Known) Diabetes Mellitus (PDM)
PDM mothers are usually older and overweight. They are insulin resistant, rather than
insulin depleted and therefore seldom go into diabetic ketoacidosis. They usually
need larger amounts of insulin to control their blood glucose values.
If it is safely achievable, women with diabetes who are planning to become pregnant
should aim to maintain their HbA1cbelow 6.1% and take folic acid 5mg daily.
Women with diabetes whose HbA1cis above 10% should be strongly advised to avoid
pregnancy.
REFER ANY KNOWN TYPE 2 PREGNANT DIABETIC TO THE NEAREST HIGH RISK
CLINIC DIRECTLY AFTER BOOKING. DO NOT STOP ANY ORAL ANTI-DIABETIC
DRUGS BEFORE REFERRAL.
Management at high risk clinic
Search for the complete medical records on the management of her disease to date.
Do a thorough medical examination: look for complications of diabetes and for signs
of long-standing diabetes.
Start on 7600 kJ diet and refer to a dietician for advice. All diabetic pregnant patients
must do moderate excercise for 30 minutes each day.
Do renal assessment: serum creatinine and urine diagnostic strips.
o If serum creatinine >120 micromol/litre, refer to a nephrologist.
o If 1+ or more proteinuria on diagnostic strips- do a full 24 hour urine protein
determination. If total protein excretion >2g/24 hours, refer to a nephrologist.
Refer to ophthalmology for retinal check-up if long-standing type 2 diabetes and no
assessment in the past year.
How to do a glucose profile at the clinic:
NPO from midnight (only water allowed).
Patient brings own breakfast to clinic.
Test fasting blood glucose level.
Eat breakfast, repeat blood glucose test 2 hours later.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
31/41
- 31
Control
AIM for a fasting value of 3.5 - 5.5 mmol/l and a 2-hour post-prandial level of
below 7mmol/l. HbA1cshould be performed every 4 weeks to monitor glycaemic
control with the aim of maintaining this value below 6.1%.
Pharmacological management of type 2 pregnant diabetics at the high risk clinic:
Stop all anti-diabetic drugs and replace with: metformin 500mg twice a day; increase
if needed to 850mg three times per day. Follow up in two weeks with a glucose
profile.
If there is poor control at follow up, admit the patient to hospital for better control.
While continuing with the oral medication, perform a 24 hour blood sugar monitoring
profile for additional insulin requirement (determine glucose values half an hour
before each main meal and 2 hours after the meal). Then add insulin to control blood
sugar. The following is suggested:
Begin an insulin regimen with Protophane (GREEN) [Humulin N] only. Start at
a dose of 0.2u/kg. If the calculated dose comes to more than 20 units, start
with 20 units. It is generally a good idea to start 2 units lower than the
calculated dose if the dose is less than 20 units and the patient has not been
on insulin before. Protophane should be administered 30 minutes before
bedtime and the patient should have a snack just before going to sleep.
Monitor the fasting glucose values and HbA1c. When the fasting morning
value remains high, Protophane (code GREEN) can be increased in a
stepwise fashion until fasting values are normal.
As a safety precaution monitor glucose level 4 hours after administration once
Protophane has been initiated or dosages modified. If fasting values are normal but
HbA1cis raised there are post-prandial excursions. Determine glucose values half an
hour before each main meal and 2 hours after the main meal (three times a day) for
24-48 hours before any changes and then add Actrapid (YELLOW) [Actrapid HM or
Humulin R] as indicated below only once fasting values have been normalised.
Identify the meal with the largest post-prandial increase and begin with Actrapid 4
units (30 minutes prior to meal). Increase by 2 units until the post-prandial value is
within the target range. If necessary apply the same principle to other meals.
As soon as the profile is satisfactory and the patient can inject herself, she can be
discharged. Mark the antenatal card as level 3 (high risk).
Follow up at the high risk/diabetic clinic according to the schedule below.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
32/41
- 32
Remember to offer home monitoring to any patient on insulin.
Review control with HbA1c 2-4 weeks after discharge along with home monitoring
values before and after meals.
Follow up of controlled type 2 diabetics at the high risk clinic:
2 weekly until 36 weeks Thereafter weekly until delivery.
Rural patients are followed up at their own clinic in conjunction with the outreach
specialist program.
Perform NT scan at 11-13 weeks if available and detail ultrasound at 20 weeks
including four-chamber view of the fetal heart and outflow tracts.
Perform a Doppler test of the umbilical artery at 24 weeks.
Perform ultrasound fetal evaluation and weight estimation at 36-38 weeks (weight
estimation clinically or with ultrasound, if available).
Perform glucose profile with each visit
Offer induction of labour at 38 weeks if certain gestation (preferable option). If
patient opts to continue with pregnancy, do weekly fetal surveillance until 41 weeks
and then induce. If gestation uncertain, perform amniocentesis and fetal lung maturity
tests.
Opt for elective caesarean section if estimated fetal weight is >4 kgat term and
the baby has a typical diabetic morphometry (AC >90thcentile, HC 50thcentile).
Management of type 2 diabetes in labour
ALL DIABETIC PATIENTS MUST DELIVER IN A HOSPITAL WITH SPECIALIST
SUPERVISION AND 24-HOUR NEONATAL RESUSCITATION FACILITIES
If the client is only on oral anti-diabetic drugs, manage the same as for GDM (protocol
A)
If she is using insulin, put up a maintenance infusion of 10 units of short-acting
(Actrapid HM or Humulin R) insulin in 1 litre of 5% dextrose and administer
intravenously at 100ml/hour.
If hourly values not maintained between 4 and 7 mmol/l:
o If blood sugar levels rise >8mmol/l, replace the maintenance infusion with a
new infusion of 12-14 units of short-acting (Actrapid HM or Humulin R)
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
33/41
- 33
insulin in 1 litre of 5% dextrose. Administer at 100 ml per hour. (Discard any
previous infusions).
o If blood sugar level is
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
34/41
- 34
PROTOCOLS FOR THE SCREENING, DIAGNOSIS AND MANAGEMENT OF DIABETES
MELLITUS IN PREGNANCY
C. Pre-gestational (known) insulin-requiring diabetes
If it is safely achievable, women with insulin dependent (IDDM) diabetes who are
planning to become pregnant should aim to maintain their HbA1cbelow 6.1% and
take folic acid 5mg daily.
Women with diabetes whose HbA1c is above 10% should be strongly advised to
avoidpregnancy.
REFER ANY KNOWN TYPE 1 (INSULIN DEPENDENT) PREGNANT DIABETIC TO THE
NEAREST HIGH RISK CLINIC DIRECTLY AFTER BOOKING. DO NOT STOP INSULIN
BEFORE REFERRAL. IT IS PREFERABLE THAT THEY RECEIVE TERTIARY CARE.
Please note that there is currently no good evidence to begin with metformin in women with
Type 1 diabetes. The goal of such an approach would be to decrease the insulin
requirements (that will increase in pregnancy) and to address the insulin resistance of
pregnancy. It is not recommended.
Management at the clinic (usually admission will be required)
Most patients on insulin will already be using short acting insulin three times a day
with intermediate or long-acting insulin at night (basal bolus). If this is not the case butthere is good control, continue with the current regime, otherwise change to the basal
bolus approach, which is the ideal.
If a change of regimen is necessary admit to hospital. Calculate total daily insulin
requirement, then administer 50% as intermediate acting (Protophane / Humulin N)
30 min before bed time (with a maximum starting dose of 30U) and 50% as short
acting insulin (Actrapid / Humulin R) 30 minutes prior to each main meal (divide
evenly over the three meals).
While on the basal bolus regimen, determine glucose values half an hour before each
main meal and 2 hours after the main meal (three times a day) and at bedtime for 24-
48 hours before any changes.
Begin with the fasting glucose value. If this is still high increase the dose of
Protophane by 2-4U increments until within the target range.
Next compare pre- and post-prandial values. If there is an increase of >2mmol/l over
meals and the postprandial value is not within the target range, add 2U Actrapid to
existing dosage until within the target range.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
35/41
- 35
In Type I diabetics it is sometimes necessary to use Protophane twice daily as the
effect lasts only for 12-18 hours (shorter in pregnancy). Consider a second dose of
Protophane when pre-prandial values at lunch and supper remain high.
All patients with IDDM must do home monitoring of blood glucose. If she does not
have the necessary equipment, motivate for this before discharge.
All insulin dependent diabetics must carry glucagon and sweets with them at all times
with detailed instructions on their use in cases of hypoglycemia.
Search for the complete medical records on the previous management of the
patients disease.
Review the records of glycaemic control and HbA1c (ideally perform HbA1c on a
monthly basis).
Perform a thorough medical examination to look for complications of diabetes and for
signs of micro-vascular disease.
An ophthalmic examination should be done (fundoscopy).
Start on a 7600 kJ diet and refer to the dietician for advice. All diabetic pregnant
patients must do moderate exercise for 30 minutes each day.
Perform renal assessment: serum creatinine and urine diagnostic strips.
o If serum creatinine >120micromol/litre, refer to a nephrologist.
o If 1+ or more proteinuria on diagnostic strips- do a full 24 hour urine protein
determination as inpatient. If total protein excretion >2g/24 hours, refer to a
tertiary diabetic unit.
Refer to ophthalmology for retinal check-up if no assessment in the past year.
Control
AIM for a fasting value of 3.5 - 5.5 mmol/l and a 2-hour post-prandial level of
below 7mmol/l. HbA1cshould be performed every 4 weeks to monitor glycaemic
control with the aim of maintaining this value below 6.1%.
As soon as the profile is satisfactory and the patient can inject herself, she may be
discharged. Mark the antenatal card as level 3 (high risk).
Follow up at a diabetic or high risk clinic according to the schedule below
Follow up of controlled type 1 diabetics at the high-risk clinic:
2 weekly until 36 weeks
Thereafter weekly until delivery.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
36/41
- 36
Rural patients can be followed up at their own clinic in conjunction with the specialist
outreach program, but must preferably stay with family or friends in a larger centre for
the duration of the pregnancy to attend the tertiary diabetic unit.
Perform NT scan at 11-13 weeks if available, and a detail ultrasound at 20 weeks
including four-chamber view of the fetal heart and outflow tracts.
Perform a Doppler test of the umbilical artery at 24 weeks. Perform ultrasound fetal evaluation and weight estimation at 36-38 weeks (weight
estimation clinically or with ultrasound, if available).
Perform glucose profile with each visit
Offer induction of labour at 38 weeks if certain gestation (preferable option). If
patient opts to continue with pregnancy, do weekly fetal surveillance until 41 weeks
and then induce. If gestation uncertain, perform amniocentesis and fetal lung maturity
tests.
Opt for elective caesarean section if estimated fetal weight is >4 kgat term and
the baby has a typical diabetic morphometry (AC >90thcentile, HC 50thcentile).
Management of type 1 diabetes in labour
ALL DIABETIC PATIENTS MUST DELIVER IN A HOSPITAL WITH SPECIALIST
SUPERVISION AND 24 HOUR NEONATAL RESUSCITATION FACILITIES
Put up a maintenance infusion of 10 units of short-acting insulin in 1 liter of 5%
Dextrose and administer intravenously at 100ml/hour as soon as patient is nil per os
Perform hourly glucose determination- must be maintained between 4 and 7 mmol/l If hourly values not maintained between 4 and 7 mmol/l:
o If blood sugar levels rise >8mmol/l, replace the maintenance infusion with a
new infusion of 12-14 units of short-acting (Actrapid HM or Humulin R)
insulin in 1 litre of 5% dextrose. Administer at 100 ml per hour. (Discard any
previous infusions).
o If blood sugar level is
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
37/41
- 37
After the delivery the patient can be returned to the insulin doses used before
pregnancy. As insulin requirements will be much less directly after the delivery, the
patient should be monitored for hypoglycemia.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
38/41
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
39/41
- 39
MAKE SURE THAT THERE IS 5% DEXTROSE IN THE IV FLUIDS IF
HGT 3.0
mmol/l)
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
40/41
- 40
Table 1 Specific antenatal care for women with diabetes
Appointment Care for women with diabetes during pregnancy
First appointment (jointdiabetes and antenatalclinic)
Offer information, advice and support in relation to optimising glycaemiccontrol.
Take a clinical history to establish the extent of diabetes-relatedcomplications.
Review medications for diabetes and its complications, review record ofglycaemic control and HbA1c. (consider performing HbA1c on a monthlybasis).
Offer retinal and/or renal assessment if these have not been undertaken inthe previous 12 months.
79 weeks Confirm viability of pregnancy and gestational age.
Booking appointment(ideally by 10 weeks)
Discuss information, education and advice about how diabetes will affect thepregnancy, birth and early parenting (such as breastfeeding and initial careof the baby).
12 weeks NT scan (pre-existing diabetes)
16 weeks Offer retinal assessment at 1620 weeks (or earlier if necessary) to womenwith pre-existing diabetes who showed signs of diabetic retinopathy at thefirst antenatal appointment.
20 weeks Offer fetal anomaly scan24 weeks Offer Doppler tests of the umbilical artery (if pre-existing diabetes)
34 weeks Offer ultrasound monitoring of fetal growth and amniotic fluid volume.
36 weeks Offer information and advice about:
timing, mode and management of birth
analgesia and anaesthesia
changes to hypoglycaemic therapy during and after birth
management of the baby after birth
initiation of breastfeeding and the effect of breastfeeding on glycaemiccontrol
contraception and follow-up.
38 weeks Do ultrasound fetal weight estimation and morphometry.Offer induction of labour, or caesarean section if indicated, at 38 weeksproviding the G.A. is certain (ultrasound at 22 weeks or before). Where G.A.is uncertain an amniocentesis and test for surfactant is indicated. Startregular tests of fetal well-being for women with diabetes who choose to awaitspontaneous labour. If the EFW of a baby is over 4000g and the baby has atypical diabetic morphometry (AC >90th centile, HC 50th centile) then anelective caesarean section should be offered to the mother.
39 weeks Offer tests for fetal well-being.
40 weeks Offer tests for fetal well-being.
41 weeks Offer tests for fetal well-being.
Note: The objective of this guideline is to offer induction of labour to women with diabetes mellitus at
38 weeks gestation. Further monitoring of the patient beyond 38 weeks applies where the offer of
induction is not accepted, where gestational age is uncertain, or where other circumstances exist.
-
8/10/2019 Diabetes in Pregnancy Western Cape Guidelines
41/41
Table 2
Currently available insulin (provincial coding list)
insulin human soluble
biosynthetic (yeast)
100units/ml ACTRAPID HM
insulin human solublebiosynthetic (E-coli)
100units/ml HUMULIN R
insulin human soluble +isophane (yeast)
30% + 70%100units/ml
ACTRAPHANE HM
insulin human Soluble +isophane (E-coli)
30% + 70%100units/ml
HUMULIN 30/70
insulin human isophanebiosynthetic (yeast)
100units/ml PROTAPHANE HM
insulin human isophanebiosynthetic (E-coli)
100units/ml HUMULIN N
insulin human lispro 100units/ml HUMALOG